AU2009229153B2 - Treatment of brain damage using umbilical cord blood cells - Google Patents

Treatment of brain damage using umbilical cord blood cells Download PDF

Info

Publication number
AU2009229153B2
AU2009229153B2 AU2009229153A AU2009229153A AU2009229153B2 AU 2009229153 B2 AU2009229153 B2 AU 2009229153B2 AU 2009229153 A AU2009229153 A AU 2009229153A AU 2009229153 A AU2009229153 A AU 2009229153A AU 2009229153 B2 AU2009229153 B2 AU 2009229153B2
Authority
AU
Australia
Prior art keywords
cord blood
umbilical cord
cell population
blood cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009229153A
Other languages
English (en)
Other versions
AU2009229153A1 (en
Inventor
Hung Li
Shinn-Zong Lin
Woei-Cherng Shyu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemCyte Inc
Original Assignee
StemCyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by StemCyte Inc filed Critical StemCyte Inc
Publication of AU2009229153A1 publication Critical patent/AU2009229153A1/en
Application granted granted Critical
Publication of AU2009229153B2 publication Critical patent/AU2009229153B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2009229153A 2008-03-28 2009-03-26 Treatment of brain damage using umbilical cord blood cells Ceased AU2009229153B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7217308P 2008-03-28 2008-03-28
US61/072,173 2008-03-28
PCT/US2009/001915 WO2009120368A2 (en) 2008-03-28 2009-03-26 Treatment of brain damage using umbilical cord blood cells

Publications (2)

Publication Number Publication Date
AU2009229153A1 AU2009229153A1 (en) 2009-10-01
AU2009229153B2 true AU2009229153B2 (en) 2015-06-11

Family

ID=41114539

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009229153A Ceased AU2009229153B2 (en) 2008-03-28 2009-03-26 Treatment of brain damage using umbilical cord blood cells

Country Status (10)

Country Link
US (1) US11318170B2 (OSRAM)
EP (1) EP2282748B1 (OSRAM)
JP (4) JP2011515470A (OSRAM)
CN (1) CN102036671A (OSRAM)
AU (1) AU2009229153B2 (OSRAM)
CA (1) CA2719740C (OSRAM)
IL (1) IL208406A0 (OSRAM)
SG (1) SG191701A1 (OSRAM)
TW (2) TW201636033A (OSRAM)
WO (1) WO2009120368A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
BR112014014560A8 (pt) * 2011-12-14 2017-07-04 Yeda Res & Dev subpopulação de monócitos humanos para tratamento de lesões do sistema nervoso central
CN103599129A (zh) * 2013-11-07 2014-02-26 唐明淇 一种人干细胞组合物在制备用于治疗阿尔茨海默症的药物中的用途
WO2015174087A1 (ja) * 2014-05-16 2015-11-19 公益財団法人先端医療振興財団 脳梗塞の予防及び／又は治療の為の医薬
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
CN108269615A (zh) * 2018-03-14 2018-07-10 南宁市第人民医院 一种脐血pH值与婴幼儿脑损伤的关系评价方法
AU2020332352A1 (en) * 2019-08-20 2022-01-20 Stemcyte Inc. Treatment of cardiovascular diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5087570A (en) 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
WO2001066698A1 (en) 2000-03-09 2001-09-13 Cryo-Cell International, Inc. Human cord blood as a source of neural tissue for repair of the brain and spinal cord
WO2001075094A1 (en) * 2000-04-04 2001-10-11 Thomas Jefferson University Application of myeloid-origin cells to the nervous system
US8062837B2 (en) 2002-02-14 2011-11-22 Stemcyte, Inc. Plasma-depleted, not erythrocyte-depleted, cord blood compositions and method of making
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
DE10330216A1 (de) * 2003-07-03 2005-01-20 Jensen, Arne Wilhelm Oluf, Prof. Dr. Verwendung von Stammzellen aus Nabelschnurblut zur Verhinderung von Hirnschäden infolge Sauerstoffmangel und zur Neuroprotektion
BRPI0511287A (pt) * 2004-05-17 2007-12-04 Univ Minnesota uso de células-tronco do sangue do cordão umbilical para tratar evento isquêmico
US20060264365A1 (en) 2005-05-18 2006-11-23 Hung Li Treatment of brain tissue damage
US7569545B2 (en) 2005-05-20 2009-08-04 Academia Sinica Methods of increasing neurotrophic factor expression
DK1926813T4 (da) 2005-09-23 2019-08-19 Tigenix S A U Cellepopulationer med immunregulatorisk aktivitet, fremgangsmåde til isolering og anvendelser
US7427597B2 (en) 2005-11-21 2008-09-23 Academia Sinica Method of treating brain tissue damages
US8329166B2 (en) 2005-12-16 2012-12-11 Academia Sinica Pluripotent olfactory stem cells
WO2010135610A2 (en) 2009-05-21 2010-11-25 Stemcyte Inc. Cell therapy for brain tissue damage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAGUCHI A ETE AL, 2004, JUN 22, 109(24): 2972-2975 *

Also Published As

Publication number Publication date
US11318170B2 (en) 2022-05-03
CN102036671A (zh) 2011-04-27
TWI593417B (zh) 2017-08-01
EP2282748A4 (en) 2012-01-11
JP2017031158A (ja) 2017-02-09
EP2282748A2 (en) 2011-02-16
EP2282748B1 (en) 2016-11-09
JP2018154634A (ja) 2018-10-04
WO2009120368A3 (en) 2010-01-07
JP2011515470A (ja) 2011-05-19
JP6401757B2 (ja) 2018-10-10
JP6655123B2 (ja) 2020-02-26
JP6138090B2 (ja) 2017-05-31
SG191701A1 (en) 2013-07-31
AU2009229153A1 (en) 2009-10-01
US20110256107A1 (en) 2011-10-20
CA2719740C (en) 2018-11-20
TW200948370A (en) 2009-12-01
TW201636033A (zh) 2016-10-16
IL208406A0 (en) 2010-12-30
JP2014237677A (ja) 2014-12-18
CA2719740A1 (en) 2009-10-01
WO2009120368A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
JP6655123B2 (ja) 臍帯血細胞を用いた脳損傷の処置
JP6190536B2 (ja) 幹細胞由来のエキソソームを有効成分に含む脳室内出血治療用薬学的組成物
US20210213068A1 (en) Pluripotent stem cell for treatment of cerebral infarction
JP2014159455A (ja) ヒト胚性幹細胞およびそれらの誘導体を含む組成物、使用方法、ならびに調製方法
WO2012156968A2 (en) Use of mesenchymal stem cells for the improvement of affective and cognitive function
JP6604492B2 (ja) 脳梗塞治療のための多能性幹細胞
Park et al. Effect of intravenous infusion of G-CSF-mobilized peripheral blood mononuclear cells on upper extremity function in cerebral palsy children
HK1153663A (en) Treatment of brain damage using umbilical cord blood cells
HK1153663B (en) Treatment of brain damage using umbilical cord blood cells
JP6994200B2 (ja) 多能性幹細胞による周産期脳障害の改善及び治療
US20250144150A1 (en) Preparation method of pharmaceutical composition for treating chronic stroke
EP3645706A1 (en) Autologous stem cell therapies for treatment of eye disease
Devesa et al. May Growth Hormone be useful for regenerative therapies with stem cells
JP2025123077A (ja) 脊髄梗塞治療のための多能性幹細胞
Sharma et al. Role of stem cell therapy in treatment of muscular dystrophy
KR20130075027A (ko) 초기 분화된 양수 줄기세포를 포함하는 요실금 치료제
Sharma et al. Cell therapy effects portrayed on positron emission tomography of the brain serve as a new dimension for autism
Zalewska Investigation of corticosterone impact on the sub-acute stage of recovery after photothrombotic stroke induction
Banfi et al. A CASE OF CHRONIC IMMUNE SENSORY POLIRADICU-LOPATHY (CISP) RESPONSIVE TO IMMUNE MODULATING TREATMENT
UA22507U (en) Method for treatment of organic lesions of central nervous system with use of allogenic embryonic nerve cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired